MoonLake Immunotherapeutics MLTX Debt Instrument Face Amount

Debt Instrument Face Amount at other companies

GTY

Getty RealtyGTY

$250M+203%

Flagstar Bank FLG

$212M0.0%

Essential Properties Realty TrustEPRT

$100M—

Stag IndustrialSTAG

$200M-60.9%

Easterly Government PropertiesDEA

$245.05M+58.0%

ImaxIMAX

$46.7M-5.6%

Other financials

Income statement

See full

Operating income-$70.0M-47.5%

Net income-$69.7M-74.5%

EPS (diluted)-$0.98-55.6%

Balance sheet

See full

Cash & equivalents$298.5M+9.9%

Total debt$100.8M+33.3%

Total equity$254.0M-37.7%

Total assets$400.4M-21.7%

Cash flow

See full

Operating cash flow-$66.3M-73.8%

CapEx--100%

Free cash flow-$66.3M-73.6%

Valuation

See full

Market cap$1.49B-45.9%

Enterprise value$1.29B-50.0%

Returns & leverage

See full

Return on equity-77.7%-221pp

Debt / equity0.4×+0.2×

Current ratio8.6×-12.5×

Where this comes from

Reported directly by MoonLake Immunotherapeutics in its filing.

Tagged under the XBRL concept us-gaap:DebtInstrumentFaceAmount.

The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about MoonLake Immunotherapeutics's debt instrument face amount.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MoonLake Immunotherapeutics's debt instrument face amount?: MoonLake Immunotherapeutics (MLTX) reported debt instrument face amount of $100M in Q1 2026.
How has MoonLake Immunotherapeutics's debt instrument face amount changed year-over-year?: MoonLake Immunotherapeutics's debt instrument face amount increased by 33.3% year-over-year, from $75M to $100M.